Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top
Discover Oncology

MicroRNA- 103 as a novel potential biomarker of poor prognosis and durg resistance in solid tumours

Published in:
Authors
Xiaoping Xia
Xiuping Weng
Tianyu Liang
Mingxia Xu
Chao Zhang
Published in
Discover Oncology | Issue 1/2025

Abstract

Backgroud

Multiple studies have reported that microRNA-103 is unregulated in a variety of tumours, involved in tumorigenesis, and associated with tumour prognosis, so a systematic review and meta-analysis were performed to determine the relationship between microRNA-103 and the prognosis of solid tumours.

Methods

The PubMed, Web of Science, and EMBASE databases were searched to retrieve articles to determine the relationship between microRNA-103 and tumour prognosis. Relevant articles were graded according to the Newcastle-Ottawa Scale (NOS). The 95% confidence interval (CI) was calculated by the fixed-effect/random-effect models and the risk ratio (RR) were summarised.

Results

Eight out of 162 retrieved articles were included in this review, with an average NOS score of 7.2 points. Four studies of tissue samples and four studies of serum samples suggested that the overexpression of microRNA-103 was associated with overall survival (RR = 2.65, 95% CI: 1.79–3.93, P = 0.000 and RR = 3.31, 95% CI: 2.04–5.36, P = 0.000, respectively).

Conclusion

This meta-analysis, combining 9 studies, found that overexpression of miRNA-103 is associated with poor prognosis in solid tumours, particularly in serum samples. Sensitivity analysis confirmed that high tissue expression correlates with poor outcomes. miRNA-103’s role in tumor progression suggests its potential as a prognostic biomarker for solid tumors, warranting further research for clinical applications.
Title
MicroRNA- 103 as a novel potential biomarker of poor prognosis and durg resistance in solid tumours
Authors
Xiaoping Xia
Xiuping Weng
Tianyu Liang
Mingxia Xu
Chao Zhang
Publication date
01-12-2025
Publisher
Springer US
Keyword
Biomarkers
Published in
Discover Oncology / Issue 1/2025
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-025-02963-9
This content is only visible if you are logged in and have the appropriate permissions.

Other articles of this Issue 1/2025

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program

Causal relationships between gut microbiota and urothelial carcinoma mediated by inflammatory cytokines and blood cell traits identified through Mendelian randomization analysis

Dynamic conditional survival nomogram for primary hepatocellular carcinoma: a population-based analysis

A two-decade bibliometric analysis of drug resistance in oral cancer research: patterns, trends, and future directions

Identification of Gαi1 as a key regulator of tumor progression in nasopharyngeal carcinoma

Connection between circulating inflammatory cytokines and non-small cell lung cancer: integrated Mendelian randomization and gene function analysis

  • Open Access
  • NSCLC
  • Analysis
SPONSORED

Adherence to injectables

In this podcast, Professor Jorge Sánchez shares his insights into identifying and addressing poor adherence to injectable therapy, offering guidance that can help to support patients with chronic diseases through their treatment journey.

Sponsor:
  • Novartis Pharma AG
Prof. Jorge Sánchez
Listen now
Podcast

Keynote webinar | Spotlight on dry eye disease

  • Live
  • Webinar | 28-05-2026 | 13:00 (CEST)

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Watch it live: 28 May 2026, 13:00–14:00 (CEST)

Prof. Harminder Dua
Prof. Sajjad Ahmad
Prof. Anat Galor
Join the webinar
Webinar
Image Credits
Adis Journal Podcast/© Adis, Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images